Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Advisory Committees Neurology Regulation

Insys May Need Convenience Argument To Save Sublingual Buprenorphine Spray

  • Analysis

Executive Summary

US FDA advisory committee will hear agency's concerns with Buvaya's effectiveness, safety, and abuse potential. 

You may also be interested in...



Keeping Track: Thumbs Up For Abbvie and GSK; Thumbs Down For Insys

The latest drug development news and highlights from our US FDA Performance Tracker.

Insys' Sublingual Buprenorphine Spray Fails At US FDA Panel, But Some Members See Future In Limited Role

Main concerns involved the delayed onset to meaningful pain relief and the safety signal of hypoxia. 

Initiator Or Facilitator? Gottlieb Reflects On First Year As Head Of US FDA

Table

View full table

Related Content

Pink Sheet

Topics

Related Companies

Tags:
Advisory Committees Neurology Regulation
Latest Headlines

1 June Marks Historic Day For Patent Protection In Europe

International Regulators Focus On Omicron XBB For Monovalent COVID-19 Vaccine

UK Parliamentarians Call For A New, Internationally Competitive Pricing System

Keeping Track: Entasis’ Antibiotic Xacduro, Two Opioid Misuse Therapies Clear US FDA; Pfizer’s Paxlovid Makes It Official

See All
UsernamePublicRestriction

Register

PS123148

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By